Petros Pharmaceuticals, Inc. - Common Stock (PTPI)
0.2797
-0.0053 (-1.86%)
Petros Pharmaceuticals Inc is a company focused on developing and commercializing innovative pharmaceutical solutions primarily aimed at addressing the needs of men’s health, particularly in the areas of erectile dysfunction and related health issues
The company is dedicated to improving the quality of life for men through its product offerings, which include prescription medications designed to enhance sexual performance and overall well-being. By leveraging scientific research and a commitment to patient care, Petros Pharmaceuticals seeks to provide effective treatment options that empower men to take control of their health and relationships.
Team composed of former FDA officials and key clinical and regulatory opinion leaders to help provide insight in preparation for collaboration with FDA
Working to identify quantum computing partnerships to strengthen our AI technology to include critical health records to better enable Rx to OTC switch candidates across multiple indications
NEW YORK, NY / ACCESSWIRE / September 3, 2024 / Petros Pharmaceuticals, Inc. (NASDAQPTPI), a company focused on expanding consumer access to medication through over-the- counter ("OTC") drug development programs, announces today that Fady Boctor, President and Chief Commercial Officer, will present a corporate overview at the H.C. Wainwright 26th Annual Global Investment Conference. The conference is being held on September 9 - 11, 2024 at the Lotte New York Palace Hotel.
Utilization of the Company's proprietary Web App showed improved self-selection utilizing an embedded validated diagnostic questionnaire compared to a live interview furthering the Company's efforts to potentially create a first-ever Rx-to-OTC switch in the ED category
Vital study aligned with FDA guidelines shows encouraging performance as Petros continues close FDA contact for a potential technology-centered Rx-to-OTC switch
Petros Pharmaceuticals specializes in men's health therapeutics. President Fady Boctor discusses the company's strategy to make key prescription medications. Petros is poised to expand within the $66.5 billion Rx-to-OTC market projected by 2033.
PTPI stock results show that Petros Pharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
